Q3 2025 Integra Lifesciences Holdings Corp Earnings Call Transcript
Key Points
- Integra Lifesciences Holdings Corp (IART) reported organic revenue growth of approximately 5% year over year, despite being below guidance expectations.
- Adjusted EPS for the quarter was $0.54, exceeding the top end of the guidance range, showcasing strong operational efficiency and cost management.
- The company successfully relaunched PriMatrix and Durepair products ahead of schedule through a dual sourcing strategy, enhancing manufacturing flexibility and resilience.
- Integra Skin manufacturing yields improved by more than 50%, and inventory levels increased by two and a half times since January, demonstrating effective operational improvements.
- The company is on track to resume production at the Braintree facility by June 2026, with plans to produce SurgiMend, PriMatrix, and Durepair, supporting future growth.
- Revenue performance was below expectations due to two supply interruptions in the CSS business and insufficient safety stock levels.
- The company's ENT business faced challenges due to reimbursement pressure in the sinuplasty balloon segment and timing of capital equipment purchases.
- MediHoney, a key product in the tissue technology segment, is undergoing remediation, impacting growth in that area.
- Private label sales declined by 12.6%, primarily due to softer commercial demand from private label partners.
- The company revised its full-year 2025 revenue and adjusted EPS guidance downward, reflecting lower than expected third-quarter revenue and updated fourth-quarter assumptions.
Good day and welcome to the Integra Lifesciences third quarter 2025 financial results. (Operator Instructions) As a reminder, this call may be recorded. I would like to turn the call over to Chris Ward, Senior Director of Investor Relations. Please go ahead.
Good morning, and thank you for joining me Integra Lifesciences third quarter 2025 earnings conference call. With me on the call this morning are Mojdeh Poul, President and Chief Executive Officer; and Lea Knight, Chief Financial Officer.
Earlier this morning, we issued a press release announcing our third quarter of 2025 financial results. The results and corresponding earnings presentation, which we will reference during the call, are available at integralife.com under investors, events and presentations, and a file named third quarter 2025.
Before we begin, I want to remind you that many of the statements made during this call may be considered forward-looking. Factors that could cause actual results to differ
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
